Skyview Capital makes significant investment in SilkTech with Series A venture round.

Skyview Ventures (Los Angeles, CA) has committed $11.2 Million in Series A venture round with SilkTech to support development of the SDP-4 ophthalmic eye drop formulation through a Phase 2B human clinical trial.

Leave a Comment